Sweden · Delayed Price · Currency is SEK SenzaGen AB Earnings Call Transcripts
Fiscal Year 2025
-
Achieved rapid growth and break-even with a unique genomics-based GARD platform, serving a $500M+ market driven by regulatory and scientific trends. Strategic focus includes innovation, regulatory approvals, and US expansion, with 85% recurring revenue.
-
SenzaGen is executing a multi-phase growth strategy centered on replacing animal testing with advanced in vitro methods, targeting regulatory leadership in medical devices and expanding into new toxicology endpoints. Recent financials show strong growth and break-even performance, with major sales acceleration expected post-2027 as regulatory acceptance increases.
-
Q3 2025 saw 18% revenue growth (constant currency), break-even EBITDA, and strong US sales, with Guard and ToxHub segments outperforming. Order book is robust entering Q4, and strategic investments in R&D and market expansion continue.
-
Order intake and sales pipeline are strong, with MedTech and cosmetics driving growth. Regulatory engagement and new test platforms support a positive outlook, while direct sales and product mix remain key financial metrics.
-
GARD-skin's inclusion in OECD TG 497 enhances defined approaches for skin sensitization, offering superior predictive performance, especially for hydrophobic and complex substances. The assay is supported by robust data, adaptable protocols, and is gaining regulatory traction, particularly in Europe.